Bacterial HA1 vaccine against pandemic H5N1 influenza virus: Evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets

Journal of Virology

Volumn 85, Issue 3, 2011, Pages 1246-1256

  Khurana, Surender ^a   Verma, Swati ^a   Verma, Nitin ^a   Crevar, Corey J ^b   Carter, Donald M ^b   Manischewitz, Jody ^a   King, Lisa R ^a   Ross, Ted M ^b   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VECTOR; HEMAGGLUTININ; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS PROTECTION; ERYTHROCYTE; ESCHERICHIA COLI; EXPERIMENTAL RABBIT; FEMALE; FERRET; HEMAGGLUTINATION; HUMAN; HUMAN CELL; INFLUENZA A (H5N1); INFLUENZA VACCINATION; LETHALITY; NASAL LAVAGE; NONHUMAN; OLIGOMERIZATION; PANDEMIC; PRIORITY JOURNAL; PROTECTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; SITE DIRECTED MUTAGENESIS; VIRUS LOAD; WEIGHT REDUCTION;

ALPHA-FETOPROTEINS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; FERRETS; GENETIC VECTORS; HEMAGGLUTINATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; NASAL MUCOSA; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RABBITS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VIRAL LOAD;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUSTELA; ORTHOMYXOVIRIDAE; ORYCTOLAGUS CUNICULUS;

EID: 78651396311     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02107-10     Document Type: Article

References (35)

1. Aguilar-Yanez, J. M., et al. 2010. An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS One 5:e11694.
2. Bizebard, T., et al. 1995. Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature 376:92-94.
3. Bosch, B. J., et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84:10366-10374.
4. Boulay, F., R. W. Doms, R. G. Webster, and A. Helenius. 1988. Posttranslational oligomerization and cooperative acid activation of mixed influenza hemagglutinin trimers. J. Cell Biol. 106:629-639.
5. Ceriotti, A., and A. Colman. 1990. Trimer formation determines the rate of influenza virus haemagglutinin transport in the early stages of secretion in Xenopus oocytes. J. Cell Biol. 111:409-420.
6. Copeland, C. S., R. W. Doms, E. M. Bolzau, R. G. Webster, and A. Helenius. 1986. Assembly of influenza hemagglutinin trimers and its role in intracellular transport. J. Cell Biol. 103:1179-1191.
7. Daniels, R. S., et al. 1985. Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell 40:431-439.
8. Doms, R. W., M. J. Gething, J. Henneberry, J. White, and A. Helenius. 1986. Variant influenza virus hemagglutinin that induces fusion at elevated pH. J. Virol. 57:603-613.
9. Doms, R. W., and A. Helenius. 1986. Quaternary structure of influenza virus hemagglutinin after acid treatment. J. Virol. 60:833-839.
10. Eisenberg, D., and A. D. McLachlan. 1986. Solvation energy in protein folding and binding. Nature 319:199-203.
11. Khurana, S., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2:15ra5.
12. Khurana, S., et al. 2009. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6:e1000049.
13. Khurana, S., et al. 2010. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One 5:e11548.
14. Lakey, D. L., et al. 1996. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. 174:838-841.
15. Maher, J. A., and J. DeStefano. 2004. The ferret: an animal model to study influenza virus. Lab. Anim. (NY) 33:50-53.
16. Matrosovich, M., and H. D. Klenk. 2003. Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Rev. Med. Virol. 13:85-97.
17. Powers, D. C., et al. 1997. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J. Infect. Dis. 175:342-351.
18. Roberts, P. C., W. Garten, and H. D. Klenk. 1993. Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin. J. Virol. 67:3048-3060.
19. Shen, S., et al. 2008. Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. J. Med. Virol. 80:1972-1983.
20. Song, L., et al. 2008. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 3:e2257.
21. Stevens, J., et al. 2006. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J. Mol. Biol. 355:1143-1155.
22. Stevens, J., et al. 2004. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303:1866-1870.
23. Takemoto, D. K., J. J. Skehel, and D. C. Wiley. 1996. A surface plasmon resonance assay for the binding of influenza virus hemagglutinin to its sialic acid receptor. Virology 217:452-458.
24. Treanor, J. J., J. D. Campbell, K. M. Zangwill, T. Rowe, and M. Wolff. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
25. Treanor, J. J., et al. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737.
26. van Riel, D., et al. 2007. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am. J. Pathol. 171:1215-1223.
27. Wang, K., et al. 2006. Expression and purification of an influenza hemagglutinin: one step closer to a recombinant protein-based influenza vaccine. Vaccine 24:2176-2185.
28. Wei, C. J., et al. 2008. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82:6200-6208.
29. Weldon, W. C., et al. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5:e12466.
30. Wiley, D. C., I. A. Wilson, and J. J. Skehel. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289:373-378.
31. Wilson, I. A., and N. J. Cox. 1990. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8:737-771.
32. Wilson, I. A., J. J. Skehel, and D. C. Wiley. 1981. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289:366-373.
33. Xu, R., et al. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328:357-360.
34. Xu, R., R. McBride, J. C. Paulson, C. F. Basler, and I. A. Wilson. 2009. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J. Virol. 84:1715-1721.
35. Zitzow, L. A., et al. 2002. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol. 76:4420-4429.